D
PharmaCorp Rx Inc. PCRX.V
TSX
Recommendation
Sell
Prev Close
$0.48
Volume
--
Avg Vol (90D)
30,195
Market Cap
$40.08M
Dividend & Yield
--
52-Week Range
$0.43 - $0.875
P/E (TTM)
--
EPS (TTM)
-$0.0293
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Fair
Volatility Index
Weak
Dividend Index
--
Headlines
Pacira BioSciences (PCRX, $23.1) entered Downtrend as Momentum indicator drops below 0 level on Apr 04, 2025
4/5/2025 - Tickeron - Stocks
Pacira BioSciences (PCRX, $23.1) Moving Average Convergence Divergence (MACD) Histogram turned negative on April 4, 2025
4/5/2025 - Tickeron - Stocks
Pacira BioSciences (PCRX, $23.1) price may climb as it broke lower Bollinger Band on Apr 04, 2025
4/5/2025 - Tickeron - Stocks
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?
4/4/2025 - Zacks Investment Research
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
4/4/2025 - Zacks Investment Research
Pacira BioSciences Inc (PCRX) Advances Gene Therapy for Osteoarthritis
4/3/2025 - GuruFocus
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and ...
4/3/2025 - GuruFocus
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
4/3/2025 - Globe Newswire
Pacira BioSciences Inc (PCRX) to Participate in Needham Virtual Healthcare Conference
4/1/2025 - GuruFocus
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual ...
4/1/2025 - GuruFocus
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
4/1/2025 - Globe Newswire
Easterly Investment Partners LLC Cuts Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)
3/28/2025 - MarketBeat
Pacira BioSciences Inc (PCRX) Shares Gap Down to $23.97 on Mar 25
3/25/2025 - GuruFocus
Simplify Asset Management Inc. Buys Shares of 37,742 Pacira BioSciences, Inc. (NASDAQ:PCRX)
3/24/2025 - MarketBeat
What is Zacks Research's Estimate for PCRX FY2027 Earnings?
3/24/2025 - MarketBeat
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Charles Schwab Investment Management Inc.
3/23/2025 - MarketBeat
The volume for Pacira BioSciences stock increased for one day, resulting in a record-breaking daily growth of 262% of the 65-Day Volume Moving Average
3/22/2025 - Tickeron - Stocks
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Connor Clark & Lunn Investment Management Ltd.
3/22/2025 - MarketBeat
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
3/21/2025 - Zacks Investment Research
Pacira BioSciences (PCRX, $23.82) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 20, 2025
3/21/2025 - Tickeron - Technical Analysis
Pacira BioSciences (PCRX, $23.82) entered Downtrend as Momentum indicator drops below 0 level on Mar 20, 2025
3/21/2025 - Tickeron - Technical Analysis
Commit To Buy Pacira BioSciences At $20, Earn 14.4% Annualized Using Options
3/19/2025 - Stock Options Channel
Wealthfront Advisers LLC Invests $1 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX)
3/16/2025 - MarketBeat
Bank of New York Mellon Corp Has $7.47 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)
3/16/2025 - MarketBeat
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
3/14/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$1.02M
EBITDA (TTM)
-$1.21M
EBIT (TTM)
-$1.61M
Net Income (TTM)
-$1.46M
Balance Sheet
Total Assets (Q)
$23.75M
Total Debt (Q)
$732.60K
Total Liabilities (Q)
$1.49M
Book Value Per Share (Q)
$0.1887
Cash Flow
Cash from Operations (TTM)
-$939.90K
Cash from Investing (TTM)
-$1.47M
Cash from Financing (TTM)
$20.07M
Net Change in Cash (TTM)
$17.65M
Filings
Filing Date
Wednesday, November 27, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Apr 14 and 18 (est)
Price History
Loading...
Beta
-0.63
7-Day Total Return
-7.69%
30-Day Total Return
-14.29%
60-Day Total Return
-5.88%
90-Day Total Return
-20.00%
Year to Date Total Return
9.09%
1-Year Total Return
128.57%
2-Year Total Return
140.00%
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Aug 06, 2024 - $0.43
52-week High
Aug 28, 2024 - $0.875
Valuation
Market Cap
$40.08M - Nano Cap
Enterprise Value
$21.97M
Price/Sales (TTM)
53.33
Price/Book (Q)
2.54
Dividends and Shares
Shares Outstanding
113.16M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.pharmacorprx.ca
Phone Number
Address
303 Wellman Lane
Saskatoon, SK S7T 0J1
Country
Canada
Year Founded
2021
Business Description
Sector
Consumer Staples
Industry
Consumer Staples Distribution and Retail
PharmaCorp Rx Inc. operates retail pharmacies under the PharmaChoice name in Canada. It offers prescription drug and custom compounding specialization services; weight loss and lifestyle... more
Weiss Ratings